

# Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic Syndrome

Anne-Laure Sellier-Leclerc,\* Veronique Fremeaux-Bacchi,<sup>†</sup> Marie-Agnès Dragon-Durey,<sup>†</sup> Marie-Alice Macher,\* Patrick Niaudet,<sup>‡</sup> Geneviève Guest,<sup>‡</sup> Bernard Boudailliez,<sup>§</sup> François Bouissou,<sup>||</sup> Georges Deschenes,<sup>¶</sup> Sophie Gie,\*\* Michel Tsimaratos,<sup>††</sup> Michel Fischbach,<sup>‡‡</sup> Denis Morin,<sup>§§</sup> Hubert Nivet,<sup>|||</sup> Corinne Alberti,<sup>¶¶</sup> and Chantal Loirat,\* for the French Society of Pediatric Nephrology

\*Assistance Publique–Hôpitaux de Paris, Service de Néphrologie Pédiatrique, Hôpital Robert Debré, Université Paris VII, Faculté de Médecine Denis Diderot, Paris; <sup>†</sup>Assistance Publique–Hôpitaux de Paris, Laboratoire d'Immunologie Biologique, Hôpital Européen Georges Pompidou, Paris; <sup>‡</sup>Assistance Publique–Hôpitaux de Paris, Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris; <sup>§</sup>Département de Pédiatrie, Hôpital Nord, Amiens; <sup>||</sup>Service de Néphrologie Pédiatrique, Hôpital des Enfants, Toulouse; <sup>¶</sup>Assistance Publique–Hôpitaux de Paris, Service de Néphrologie Pédiatrique, Hôpital Trousseau, Paris; <sup>\*\*</sup>Service de Néphrologie, Hôpital de Pontchaillou, Rennes; <sup>††</sup>Service de Néphrologie, Hôpital de la Timone, Marseille; <sup>‡‡</sup>Service de Pédiatrie, Hôpital Hautepierre, Strasbourg; <sup>§§</sup>Service de Pédiatrie 1, Hôpital Arnault de Villeneuve, Montpellier; <sup>|||</sup>Service de Néphrologie, Hôpital de Clocheville, Tours; and <sup>¶¶</sup>Assistance Publique–Hôpitaux de Paris, Hôpital Robert Debré, Unité d'Epidémiologie Clinique, Paris, France

## ABSTRACT

Mutations in factor H (*CFH*), factor I (*IF*), and membrane cofactor protein (*MCP*) genes have been described as risk factors for atypical hemolytic uremic syndrome (aHUS). This study analyzed the impact of complement mutations on the outcome of 46 children with aHUS. A total of 52% of patients had mutations in one or two of known susceptibility factors (22, 13, and 15% of patients with *CFH*, *IF*, or *MCP* mutations, respectively; 2% with *CFH*+*IF* mutations). Age <3 mo at onset seems to be characteristic of *CFH* and *IF* mutation-associated aHUS. The most severe prognosis was in the *CFH* mutation group, 60% of whom reached ESRD or died within <1 yr. Only 30% of *CFH* mutations were localized in *SCR20*. *MCP* mutation-associated HUS has a relapsing course, but none of the children reached ESRD at 1 yr. Half of patients with *IF* mutation had a rapid evolution to ESRD, and half recovered. Plasmatherapy seemed to have a beneficial effect in one third of patients from all groups except for the *MCP* mutation group. Only eight (33%) of 24 kidney transplantations that were performed in 15 patients were successful. Graft failures were due to early graft thrombosis (50%) or HUS recurrence. In conclusion, outcome of HUS in patients with *CFH* mutation is catastrophic, and posttransplantation outcome is poor in all groups except for the *MCP* mutation group. New therapies are urgently needed, and further research should elucidate the unexplained HUS group.

*J Am Soc Nephrol* 18: 2392–2400, 2007. doi: 10.1681/ASN.2006080811

Hemolytic uremic syndrome (HUS) is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, secondary to thrombotic microangiopathy (TMA) lesions. Postdiarrheal or typical HUS, the most frequent form in children, is caused by infection with Shiga toxin (Stx)-producing *Escherichia coli*. A variety of triggers for non-Stx-associated HUS have been identified, including *Streptococcus pneu-*

*moniae* and various nonenteric infections, viruses,

Received August 1, 2006. Accepted April 12, 2007.

Published online ahead of print. Publication date available at [www.jasn.org](http://www.jasn.org).

**Correspondence:** Dr. Chantal Loirat, Service de Néphrologie, Assistance Publique–Hôpitaux de Paris, Hôpital Robert Debré, 48 Boulevard Sérurier, 75 019 Paris, France. Phone: +33-1-4003-2146; Fax: +33-1-4003-2468; E-mail: [chantal.loirat@rdb.aphp.fr](mailto:chantal.loirat@rdb.aphp.fr)

Copyright © 2007 by the American Society of Nephrology

**Table 1.** Complement component assessment in previously undescribed nine patients with *CFH* and *IF* gene mutations<sup>a</sup>

Patient	Mutation	SCR	Effect <sup>b</sup>	F/S	Inheritance	C3 (mg/L) <sup>c</sup>	CFH (%) <sup>c</sup>
<i>CFH</i> gene							
new mutations							
4 <sup>d</sup>	554G→T	3	A161S	F	HE	501	69
5	1978A→T	11	Q635D	S	HE	563	76
known mutations <sup>10</sup>							
3	3767del4bp	20	Frameshift	S	HO	234	4
10	3645C→T	20	S1191L	S	HE	1030	110
Patient	Exon	Mutation	Effect	F/S	Inheritance	C3 (mg/L)	IF (%) <sup>c</sup>
<i>IF</i> gene							
new mutations							
15	12	1246A→C	I398L	S	HE	348	70
17	12	1297A→G	I415V	S	HE	1000	186
11 <sup>e</sup>	4	548A→G	H165R	S	HE	290	ND
known mutations <sup>10</sup>							
12	—	IVS12+5	SD	S	HE	500	91
14	—	IVS12+5	SD	S	HE	190	74

<sup>a</sup>aHUS, atypical hemolytic uremic syndrome; CFH, factor H; F, familial; HE, heterozygous; HO, homozygous; IF, factor I; MCP, membrane cofactor protein; S, sporadic; SD, splice defect.

<sup>b</sup>Numbering of base pairs/amino acids is adapted as previously reported.<sup>10</sup>

<sup>c</sup>Normal range (−2 SD to 2 SD): C3 660 to 1260 mg/L; CFH 70 to 130%; IF 70 to 130%.

<sup>d</sup>Brother of patient 4 presented with aHUS, with favorable outcome but without mutation of *CFH*, *IF*, or *MCP*.

<sup>e</sup>Patient 11 presented with a mutation in *CFH* gene (case 8 in Dragon-Durey *et al.*<sup>17</sup>) and a mutation in *IF* gene.

drugs, malignancies, transplantation, or autoimmune disease.<sup>1–3</sup> When there is no identified preceding illness, less frequently, the disease is known as atypical HUS (aHUS) and can occur at any age, from the neonatal period to adult age, with familial and sporadic cases.<sup>4,5</sup> In patients with aHUS, mutations were reported in the genes of three proteins that regulate complement alternative pathway and protect host cellular surfaces from complement activation: Factor H (CFH), membrane co-factor protein (MCP or CD46), and factor I (IF).<sup>6–9</sup> Up to now, at least 70 complement genetic abnormalities have been reported in adults and children with aHUS.<sup>10,11</sup> It was shown that aHUS was secondary to complement dysregulation in approximately 50% of patients.<sup>12</sup> In addition, acquired functional CFH deficiency as a result of anti-CFH antibodies has been reported in three children.<sup>13</sup> The identification of congenital ADAMTS 13 deficiency reclassified a subgroup of aHUS as congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).<sup>14</sup> The aims of this study were to document the frequency of each of these genetic complement-dependent risk factors of aHUS among pediatric patients and to provide a comprehensive characterization of the clinical findings according to the genetic background that could help to define prognosis and therapeutic guidelines according to clinicobiological characteristics.


## RESULTS

### Complement Component Assessment and Molecular Characterization of *CFH*, *MCP*, and *IF* Mutations


Among the 46 children, 10 (22%) had a *CFH* mutation, six (13%) had an *IF* mutation, one (2%) had a *CFH* and an *IF*

mutation, and seven (15%) had an *MCP* mutation. Twenty-two (48%) children had no genetic defect either in *CFH* or in *IF* or *MCP* genes by direct sequencing analysis of all exons of each gene and are designated as “unexplained aHUS.”

Among the 22 mutations, 13 have been reported by our group and were associated with complement haploinsufficiency<sup>9,15–17</sup> and four were previously identified in unrelated patients with aHUS by other groups (*CFH*: S1191L, 1232delTAGA; *IF*: IVS12 + 5, G243D).<sup>10,12,18</sup> Five new mutations were identified (*CFH*: A161S and Q635D; *IF*: I398L, I415V, and H165R). All mutations were scattered throughout the coding regions of the three genes, including *CFH* (Table 1). None of these mutations occurred in the controls groups. Six



**Figure 1.** C3 levels according to complement mutation. —, Lower limit of normal C3 (660 mg/L, −2 SD). Patient 11 with *CFH* and *IF* mutation not shown (C3 290 mg/L).



**Figure 2.** Individual clinical course and genetic analysis of the 46 patients with atypical hemolytic uremic syndrome (aHUS). M, male; F, female; ↓, HUS flare; —, native kidneys functioning; □, ESRD; \*, fresh frozen plasma (FFP) infusions; °, plasma exchanges (PEX); - - -, long-term FFP treatment; + + +, long-term PEX treatment. Patients 1 and 2 are first cousins. Patients 20 and 21; 28, 29, and 30; and 33 and 34 are siblings. Functional consequences of the mutations and patients have been previously reported for a, b, c, d, and e, respectively.<sup>15,6,29,12,16</sup>

mutations were homozygous (three patients with *CFH* mutation, born from consanguineous parents, and three with *MCP* mutations).

C3 levels were low in nine of the 10 patients with *CFH* mutation, the patient (patient 11) with *CFH* and *IF* mutation, four of the six with *IF* mutation, and four of the 22 with unexplained aHUS. C3 levels were significantly different among the four groups ( $P = 0.002$ ) with levels being the lowest in the *CFH* and *IF* mutation groups (Figure 1). *CFH* levels were nearly undetectable in the three patients with homozygous *CFH* mutation and mildly decreased in five of the eight patients with heterozygous *CFH* mutation (including patient 11). *IF* levels were normal in all patients, including those with *IF* mutation. *MCP* expression was very low in the three patients with homozygous *MCP* mutation and approximately 50% of normal in the heterozygous patients.

**Clinical Characteristics**

*Familial/Sporadic.*

The gender ratio was similar among the group with or without complement mutations (Figure 2, Table 2). Fourteen patients had familial aHUS associated with *CFH*, *IF*, or *MCP* mutation in three, one, and one families, respectively. Four other families belong to the unexplained group (Table 2). In two families, only one of the two siblings with the disease had either *CFH* (patient 4) or *IF* (patient 16) mutation (Tables 1 and 2). In both families, the sibling with the mutation (patients 4 and 16) had a severe outcome, whereas the sibling without the mutation (not included in the study) had a favorable outcome.

*Onset.*

Age at onset of symptoms ranged from 1 d to 16 yr, with 32 (70%) of 46 with onset before age 2 (Figure 3, Table 2). Of the eight patients with onset before 3 mo of age, three had *CFH* mutation, four had *IF* mutation, and one had unexplained HUS. Seventy percent of the patients with *CFH* mutation (seven of 10) and 67% with *IF* mutation (four of six) had onset before age 1. No patient with *CFH*, *IF*, or *CFH+IF* mutations had onset later than age 4. No patients with *MCP* mutation had onset before age 1. Overall, age at onset was significantly different among the four groups ( $P = 0.02$ ), the youngest being in the *CFH* and *IF* mutation groups. HUS onset followed a triggering event (upper respiratory tract infection, fever, diarrhea) in 29 (63%) patients from all subgroups. In particular, prodromic diarrhea preceded HUS in 13 (28%) patients from all subgroups, including infection with 0157:H7 *E. coli* in patient 20 with *MCP* mutations (Y155D and IVS8-2), familial HUS (brother of patient 21), and subsequent nonpostdiarrheal relapses (Figure 2).

ESRD; \*, fresh frozen plasma (FFP) infusions; °, plasma exchanges (PEX); - - -, long-term FFP treatment; + + +, long-term PEX treatment. Patients 1 and 2 are first cousins. Patients 20 and 21; 28, 29, and 30; and 33 and 34 are siblings. Functional consequences of the mutations and patients have been previously reported for a, b, c, d, and e, respectively.<sup>15,6,29,12,16</sup>

**Table 2.** Summarized clinical course in the various subgroups of aHUS<sup>a</sup>

Parameter	Mutations			
	CFH	IF	MCP	No
n	10	6	7	22
Age at onset (median [range]) <sup>b</sup>	6 mo (3 d to 3 yr, 6 mo)	2 mo (1 d to 3 yr, 8 mo)	4 yr, 6 mo (1 yr, 6 mo to 11 yr, 3 mo)	1 yr, 1 mo (15 d to 15 yr)
Newborn (<3 mo)	3	4	0	1
Male/female <sup>c</sup>	4/6	5/1	3/4	13/9
Familial HUS (no. of pedigree) <sup>d</sup>	4 (3) <sup>g</sup>	1 (1) <sup>g</sup>	2 (1)	7 (4)
Relapsing HUS (%) <sup>e</sup>	3 (30)	2 (33)	6 (86)	13 (59)
CNS involvement	1	1	0	3
Plasmatherapy (efficient/not efficient)	2/4	2/1	0/4	3/5
Outcome <sup>f</sup>				
death	2	1	0	1
ESRD (as soon as first flare)	6 (4)	2 (2)	2 (0)	6 (4)

<sup>a</sup>CNS, central nervous system.

<sup>b</sup> $P = 0.02$ ; age at onset is significantly different among the four groups, with the youngest being in the *CFH* and *IF* mutation groups.

<sup>c</sup> $P = 0.37$ ; gender ratio is not different among the four groups.

<sup>d</sup> $P = 0.85$ ; distribution of familial HUS is not different among the four groups.

<sup>e</sup> $P = 0.10$ ; proportion of patients with relapsing HUS is not different among the four groups.

<sup>f</sup>Outcome within the 10 yr after onset is indicated. One patient in the *CFH* mutation group had ESRD at death.


<sup>g</sup>Brother of patients 4 and 16 were not included in the study (aHUS after the end of the recruitment of patients). They have no mutation of *CFH* or *IF*, suggesting the presence of another genetic unknown factor.

### Manifestations at the First Flare and Clinical Course.

All patients except two presented with anemia with schizocytosis (mean hemoglobin [Hb] 6.7 g/dl [3.7 to 9.0 g/dl]) and 39 (85%) of 46 with thrombocytopenia (mean platelet count 55 G/L [5 to 145 G/L]). Thirty-eight (83%) of the 46 patients had acute renal failure at first flare of aHUS (mean serum creatinine 338  $\mu$ mol/L [90 to 755  $\mu$ mol/L]). Eight (17%) patients presented with proteinuria and hematuria, without renal failure (mean serum creatinine 54  $\mu$ mol/L [40 to 63  $\mu$ mol/L]).

Eleven (24%) of the 46 had ESRD as soon as the first episode of the disease. Twenty-five (54%) patients had from two to

nine new episodes of HUS at intervals from 1 mo to 9 yr, with nine patients having four episodes or more (Figure 2). The proportion of patients with relapsing HUS was not significantly different among the four groups (Table 2). However, overall number of relapses during the 10 yr after onset was significantly different among the four groups ( $P = 0.03$ ), the highest number being in the *MCP* mutation and unexplained groups. Relapse with complete recovery was common in the patients with *MCP* mutation and unexplained HUS. By contrast, in the *CFH* mutation group, eight (80%) of 10 either died or reached ESRD at first flare ( $n = 5$ ) or after relapses ( $n = 3$ ), whereas an additional patient reached ESRD after 10 yr of follow-up. Three (50%) of the six patients with *IF* mutation either died or had ESRD, two of them at first flare. The patient with *CFH*+*IF* mutation had ESRD at first flare. Two (29%) of seven patients with *MCP* mutation had ESRD after one to two relapses 2 to 3.5 yr after onset, and one additional patient reached ESRD after seven relapses of HUS 37 yr after onset. Seven (32%) of the 22 patients with unexplained HUS either died ( $n = 1$ ) or had ESRD ( $n = 6$ ) at first flare of HUS or within a few months. One additional patient reached ESRD 15 yr after onset. Extrarenal involvement was uncommon. Four patients, including one with *CFH* mutation and three with unexplained HUS, had cerebrovascular events, as well as pulmonary involvement in one of the latter.



**Figure 3.** Age at onset of aHUS and outcome during the year after onset of the 46 patients. H, *CFH* mutation; I, *IF* mutation; MCP, *MCP* mutation; ?, unexplained HUS; ▨, ESRD or death during first year after onset; □, alive with functioning kidneys 1 yr after onset.

### Outcome

Poor outcome, defined as death or ESRD within 1 yr after onset, was observed in 17 (37%) of the 46 patients (Figures 2 and 3, Table 2). Four (9%) of the 46 patients died within a few weeks or months after onset (from sequelae of cerebrovascular events, pulmonary hemorrhage concomitant with hemolysis and thrombocytopenia, *Staphylococcus aureus* septicemia, and



multivisceral failure with diffuse TMA at postmortem histology). The risk for poor outcome (patient 11 not included) within the first year was significantly related to serum creatinine level at first episode. No other factors were found to be significantly linked with poor outcome during the first year (Table 3).

Overall, renal survival was significantly different among the four groups (log-rank test,  $P = 0.03$ ; Figure 4). Indeed, at 1 yr after onset, it was 40.6% in the *CFH* mutation group, 50% in the *IF* mutation group, 100% in the *MCP* mutation group, and 68% in the unexplained group. At 5 yr, the percentages were 27, 50, 62, and 68%, respectively (Figure 4).

**Plasmatherapy**

Twenty-two patients received plasmatherapy, most often daily during 7 to 10 d, and, when successful, subsequently tapered to once every week or every 2 wk (Figure 2, Table 2). Of the 22, 16 received fresh frozen plasma (FFP) infusions (10 to 20 ml/kg), four received plasma exchanges (PEX; 40 to 50 ml/kg per session) with FFP for volume restitution, and two received both treatments. Seven (32%) of 22 patients had a positive response, including two patients with homozygous *CFH* deficiency. Among the *MCP* mutation group, favorable outcome occurred in eight (89%) of nine episodes that were treated with plasmatherapy and 15 (88%) of 17 untreated episodes.

**Posttransplantation Course**


A total of 24 kidney transplantations were performed in 15 patients (Figure 5), with cadaveric donors in all except one. All patients except one had bilateral nephrectomy before transplantation.

Sixty-six percent of patients (10 of 15) had at least one graft failure (Figure 5). During the first year, 12 (50%) grafts failed: Eight from thrombosis between 0 to 45 d after surgery, three from HUS recurrence, and one from cytomegalovirus infection. Six (25%) patients had an uneventful clinical course during 5 to 15 yr after transplantation. One of them (patient 8) had histologic TMA at graft biopsy 12 yr after transplantation. Two patients had functioning graft 2 yr after transplantation despite HUS recurrence. Four grafts were lost subsequently, from recurrence in two patients and rejection in two other patients.

**Table 3.** Relationships between age at onset, familial incidence of HUS, serum creatinine at first flare, and C3 level and severity of outcome at 1 yr<sup>a</sup>

Risk Factors	ESRD or Death within the Year after Onset	
	HR (95% CI)	P
Age at onset (per year)	0.98 (0.97 to 1.00)	0.16
Familial/sporadic HUS		0.44
familial HUS (n = 14)	1	
sporadic HUS (n = 31)	1.56 (0.50 to 4.85)	
Serum creatinine at first flare (each 50 points)	1.12 (1.01 to 1.24)	0.03
C3 level	0.99 (0.98 to 1.00)	0.42

<sup>a</sup>CI, confidence interval; HR, hazard ratio.




**Figure 4.** Renal survival, according to complement mutation, up to 10 yr of follow-up. Patient 11 with *CFH* and *IF* mutation was not included.

Among the five patients with *CFH* mutation, one of the six (16.6%) kidney grafts had an uneventful course during 12 yr after transplantation. The cause of early (<1 yr after transplantation) graft failure was HUS recurrence (n = 1) or renal artery thrombosis (n = 2). The patient with *CFH*+*IF* mutations had an uncomplicated course during 5 yr. Among the two patients who had *IF* mutation and received a transplant, one had an uncomplicated course and normal graft function 3 yr, 6 mo after transplantation. The other one had HUS recurrence at day 15 and returned to dialysis 5.5 yr after transplantation. The patient who had *MCP* mutation and received a transplant had an uneventful posttransplantation course but lost the graft after 5.6 yr from rejection as a result of noncompliance.

Six children with unexplained aHUS received 14 renal transplants. Ten (71%) failed from early renal artery/vein thrombosis (n = 6), HUS recurrence (n = 2), rejection as a result of noncompliance (n = 1), or cytomegalovirus infection (n = 1).

**DISCUSSION**

This article is the first to describe the genetic susceptibility factors and the clinical outcome in 46 children with aHUS. We demonstrate that aHUS with pediatric onset is a disease of complement dysregulation in roughly half of cases. We found *CFH* mutations in 22% of the patients and an equivalent percentage of *IF* (13%) and *MCP* mutations (15%). Three important clinical characteristics can be emphasized. The first is age at onset. Onset before 3 mo of age seems to be a characteristic of *CFH* and *IF* mutation-associated aHUS. By contrast, onset before age 1 has not been observed in children with *MCP* mutation, whereas unexplained HUS may start at any age, from the neonatal period to adolescence. The second is that creatinine level at first episode is significantly correlated with the risk for ESRD or death during the first year. The third important point is that the clinical course and prognosis were not similar in the various subgroups. The overall rate of ESRD was 43%



**Figure 5.** Posttransplantation course. ↓, transplantation; —, functioning graft; ↓↓, adverse event, as indicated; □, ESRD; \*, FFP infusions; °, PEX; ---, long-term FFP treatment; ...., intravenous Ig.

(20 of 46), as reported in a series of pediatric aHUS.<sup>5</sup> As previously observed by Caprioli *et al.*,<sup>12</sup> we show that the most severe prognosis was in the *CFH* mutation group, 70% of whom reached ESRD during childhood, most frequently as soon as at first episode. The clinical course of *MCP* mutation-associated aHUS is clearly different: These patients have a relapsing course, but none reached ESRD at 1 yr. It is interesting that patients with *IF* mutation seem to have a more variable outcome, because half had rapid evolution to ESRD or death and half recovered. Patients with unexplained aHUS have a variable outcome, suggesting various pathophysiologic mechanisms. Familial forms accounted for 30.4% in our series, ob-

served within all subgroups. We identified two cases of familial aHUS that illustrate phenotypic and genetic heterogeneity between siblings. In each family, only the sibling with either *CFH* or *IF* mutation had a severe outcome. These observations suggest the presence of additional uncharacterized genetic abnormalities. The two *CFH* and *IF* mutations might have as-yet-unknown functional consequences playing the role of severity factors. However, they could also correspond to rare polymorphisms (although they have been identified only in patients with aHUS and never in control subjects).

We also observed that infectious episodes, especially gastrointestinal, appeared as triggering events of HUS in all subgroups.<sup>12</sup> Moreover, *E. coli* 0157 infection was the triggering event of the first episode of HUS in one child with *MCP* mutation. Considering these results, diarrhea and even *Stx-E. coli* infection do not preclude the possibility that the underlying diagnosis is aHUS. This confirms that complement anomalies are risk factors rather than the only cause of the disease.

Ten (22%) of the 46 patients with aHUS had *CFH* mutation, a proportion in agreement with that of 14 to 33% reported in the literature.<sup>12,19,20</sup> As in our patients, the majority of *CFH* mutations reported in the literature are heterozygous. A total of 60% of the mutations published up to now are located within the C-terminal domain of the protein, particularly in SCR20, which induces a reduced ability of *CFH* to bind to surface-bound C3b and to the polyanions of the endothelial cells.<sup>10,11,21,22</sup> However, in our pediatric patients, only 30% of *CFH* mutations were located in SCR20. Another 30% were in SCR15, and other mutations were scattered over the *CFH* gene. These data indicate that sequencing of *CFH* gene cannot be limited to SCR16 to 20 in children with aHUS, because this may miss 70% of *CFH* mutations. In addition, 72% of patients with *CFH* mutation presented with quantitative *CFH* deficiency as opposed to approximately 20% reported by Caprioli *et al.*<sup>12</sup> The proportion of 15% of our patients who were found to have *MCP* mutation is in agreement with that of 10 to 15% previously reported.<sup>12,19</sup> In our pediatric cohort, 13% of patients had *IF* mutation. This is more than the proportions reported (between 2 and 4.5%).<sup>12,19,23</sup> The frequency of familial cases in each cohort or the sensitivity of methods for mutation detection may explain the difference. For the everyday practice, our data show that the association of early-onset aHUS and low C3 is indicative of *CFH* or *IF* mutation. However, the absence of low C3 is not predictive of a favorable outcome. We recommend determination of C3, *CFH*, *IF*, and *MCP* levels and complete genetic screening of *CFH*, *IF*, and *MCP* genes in all patients with aHUS.

As reported by several authors, patients with homozygous *CFH* mutations were those who clearly benefited from receiving normal *CFH* by FFP infusions.<sup>24–26</sup> However, the benefit of plasmatherapy is not clear for the majority of patients with aHUS. Most patients of our series received 10 ml/kg FFP infusions that may not be sufficient to change the severity of the evolution. A few case reports from the literature suggest that PEX that bring at least 40 ml/kg FFP are associated with a more favorable outcome in *CFH* mutation-associated aHUS.<sup>27,28</sup>

Two children with *IF* mutation in this series and a few cases in the literature<sup>18,23</sup> seemed to respond to FFP infusions or PEX, which has some logic because IF is brought by plasma. In practice, recommended treatment for children with aHUS should be aggressive PEX therapy. The decision of this treatment is difficult in patients with mild renal involvement.

The posttransplantation course analysis suggests several remarks. First, the overall success of transplantation was poor: Only eight (33%) of the 24 kidney grafts that were performed in 15 patients were functioning at last follow-up. It is interesting that a high proportion of failures were due to causes other than recurrence, mainly vascular thrombosis (eight of 16 graft failures). This has not been previously reported and suggests additional risk factors to thrombosis in patients with aHUS. In our pediatric series, posttransplantation HUS recurrence occurred in 53% of the whole group of aHUS and in 80% of patients with *CFH* mutation, a proportion similar to that of 74% reported by Bresin *et al.*<sup>29</sup> The reason that 20% of patients with *CFH* mutation have no recurrence is unknown. The reported risk for posttransplantation HUS recurrence in patients with *IF* mutation was 100%.<sup>30</sup> Nevertheless, among the two patients with *IF* mutation in our series who received a transplant and who happened to have the same nucleotide substitution, one had HUS recurrence and the other one had no recurrence during the 3 yr of follow-up. Amazing, the patient with both *CFH* and *IF* mutation had an uncomplicated posttransplantation course. The only patient with *MCP* mutation of our cohort who received a transplant had no recurrence, as most frequently observed in patients with *MCP* aHUS,<sup>30</sup> a logic issue because one may expect that the graft brings normal *MCP*. Another noticeable observation is that in several patients, the posttransplantation course was less severe than that of the native HUS. Overall, of eight patients with posttransplantation HUS recurrence, five (62%) had preserved sufficient graft function during at least 1 yr, up to 5 yr. Several groups have reported the influence of polymorphisms of *MCP* and *CFH* in the susceptibility to HUS.<sup>19,31,32</sup> The reason that posttransplantation HUS recurrence may be less severe than primary HUS could be related to the important role of *MCP*, a protein that is highly expressed in the kidney, in the severity of the disease.

The outcome of HUS in patients with *CFH* mutation is catastrophic. New therapies are urgently needed. Liver or combined liver and kidney transplantation has been disappointing,<sup>33–35</sup> until the recent report of one successful case under plasmatherapy.<sup>36</sup> Intensive plasmatherapy is the only therapeutic option. The administration of *CFH* concentrate to treat HUS and to prevent posttransplantation recurrence ought to be an easier option in a near future.

## CONCISE METHODS

### Definitions

HUS first episode and relapses were defined on the basis of Hb levels <10 g/dl with fragmencytosis and/or thrombocytes <150 G/L, serum

creatinine >97th percentile according to age, and/or proteinuria >1+. Criteria for aHUS were age of onset before 3 mo and/or absence of diarrhea and/or progressive onset and/or relapses of HUS and/or familial HUS. Remission was defined by normalization of Hb and thrombocytes count and normalization or stabilization of serum creatinine level. These criteria also defined positive effect of plasma-therapy, when observed within 10 d of treatment. Outcome category was classified as death, ESRD, or functioning kidneys.

### Patients

From 2002 to 2005, we studied 46 patients who had aHUS of pediatric onset (before age 16) and were known to pediatricians who were affiliated with the French Society of Pediatric Nephrology. Of these 46, 11 were included prospectively and 35 were patients who previously were known to clinicians. All patients except for patient 20 (see the Onset section) were negative for *Stx-E. coli* infection (PCR for *Stx1* and *Stx2* genes in stools; serum Ig against LPS of 0157, 0103, 026, 0145, 091, 011, and 0128 *Stx-E. coli*). ADAMTS 13 activity was normal in all patients. None of the 46 patients had anti-*CFH* autoantibodies. Four patients were black and one was Asian. Other patients were white. Twenty-six (56%) patients were male, and 20 (44%) were female. All patients were previously healthy, except for patient 22, who had glomerulonephritis with C3 deposits 6 yr before HUS. Sixteen patients have been reported previously (seven, two, and seven with *CFH*, *IF*, and *MCP* mutations, respectively).<sup>9,15–18</sup>

### Assays for Complement Components and Genetic Screening

Informed consent for DNA analysis was obtained from parents and children when old enough. EDTA plasma samples were stocked at –80°C. Plasma protein concentrations of C3 and *CFH*, *IF*, and *MCP* expression (using cytometry analysis with CD46 PE antibodies) were measured as described previously.<sup>9,16,17</sup> Direct sequencing of all *CFH*, *IF*, or *MCP* exons was undertaken in all 46 patients. Primers have been previously described.<sup>6,12,15</sup> To determine whether a mutation was also present in a control collective and therefore more likely be a rare polymorphism than a deleterious mutation, we analyzed a control population that consisted of 100 locally recruited white and 20 black healthy subjects.

### Statistical Analyses

End point of the study was to analyze the risk factors of poor prognosis (ESRD or death). Results were expressed as numerical values and percentages for categorical variables and median (range) for continuous variables. Comparisons between groups were based on nonparametric tests. An event was defined by the occurrence of ESRD or death. Times to first event were computed between date of disease onset and date of first event and were censored at 10 yr (thus eliminating two events at 18 and 36 yr of follow-up). They were displayed using Kaplan-Meier curves and were compared between mutation groups by the log-rank test. A piecewise Cox model was fit to study the relationship between patient characteristics and ESRD or death within the year of onset. Results were expressed as hazard ratio (HR) and 95% confidence interval (95% CI). All tests were two-sided. Patient 11 with *CFH* and *IF* mutation was excluded from statistical analysis.



## ACKNOWLEDGMENTS

This work was supported by the Délégation Régionale à la Recherche Clinique, Assistance Publique-Hôpitaux de Paris (grants P 010709, CRC 01019, and PHRC AOM 05130).

We gratefully acknowledge the colleagues who participated in this study: E. Berard, Hôpital de l'Archet, Nice; P. Cochat, Hôpital Edouard Herriot, Lyon; P.H. Eckart, CHU de Caen; F. Janssen, Hôpital Universitaire Reine Fabiola, Bruxelles; and M. Seligman, CH de Luxembourg.

## DISCLOSURES

None.

## REFERENCES

- Ruggenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. *Kidney Int* 60: 831–846, 2001
- Noris M, Remuzzi G: Hemolytic uremic syndrome. *J Am Soc Nephrol* 16: 1035–1050, 2005
- Loirat C, Taylor M: Hemolytic uremic syndromes. In: *Pediatric Nephrology*, 5th Ed., edited by Avner ED, Harmon WE, Niaudet P, Philadelphia, Lippincott Williams & Wilkins, 2003, pp 887–915
- Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, Trachtman H: Non-enteropathic hemolytic uremic syndrome: Causes and short-term course. *Am J Kidney Dis* 43: 976–982, 2004
- Taylor CM, Chua C, Howie AJ, Risdon RA: Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. *Pediatr Nephrol* 19: 419–425, 2004
- Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turmpenny P, Goodship JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. *Kidney Int* 53: 836–844, 1998
- Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. *Proc Natl Acad Sci U S A* 100: 12966–12971, 2003
- Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G: Familial haemolytic uraemic syndrome and an MCP mutation. *Lancet* 362: 1542–1547, 2003
- Fremaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH: Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. *J Med Genet* 41: e84, 2004
- Saunders RE, Abarrategui-Garrido C, Fremaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodriguez de Cordoba S, Sanchez-Corral P, Skerka C, Zipfel PF, Perkins SJ: The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: Update and integration of membrane cofactor protein and factor I mutations with structural models. *Hum Mutat* 28: 222–234, 2006
- Dragon-Durey MA, Fremaux-Bacchi V: Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. *Springer Semin Immun* 27: 359–374, 2005
- Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G: Genetics of HUS: The impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. *Blood* 108: 1267–1279, 2006
- Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremaux-Bacchi V: Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 16: 555–563, 2005
- Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D: Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. *Semin Thromb Haemost* 32: 90–97, 2006
- Fremaux-Bacchi V, Sanlaville D, Menouer S, Blouin J, Dragon-Durey MA, Fischbach M, Vekemans M, Fridman WH: Unusual clinical severity of complement membrane cofactor protein-associated hemolytic-uremic syndrome and uniparental isodisomy. *Am J Kidney Dis* 49: 323–329, 2007
- Fremaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP: Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 17: 2017–2025, 2006
- Dragon-Durey MA, Fremaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L: Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: Report and genetic analysis of 16 cases. *J Am Soc Nephrol* 15: 787–795, 2004
- Nilsson SC, Karpman D, Vaziri-Sani F, Kristofferson AC, Salomon R, Provot F, Fremaux-Bacchi V, Trouw LA, Blom AM: A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. *Mol Immunol* 44: 1845–1854, 2006
- Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Berges LC, Lopez-Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S: Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. *Hum Mol Genet* 14: 703–712, 2005
- Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Konigsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF: Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries. *J Med Genet* 40: 676–681, 2003
- Jozsi M, Heinen S, Hartmann A, Ostrowicz CW, Halbich S, Richter H, Kunert A, Licht C, Saunders RE, Perkins SJ, Zipfel PF, Skerka C: Factor H and atypical hemolytic uremic syndrome: Mutations in the C-terminus cause structural changes and defective recognition functions. *J Am Soc Nephrol* 17: 170–177, 2006
- Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship TH: Factor H mutations in hemolytic uremic syndrome cluster in exons 18–20, a domain important for host cell recognition. *Am J Hum Genet* 68: 485–490, 2001
- Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship TH: Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 16: 2150–2155, 2005
- Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L: Familial hemolytic uremic syndrome associated with complement factor H deficiency. *J Pediatr* 138: 412–417, 2001
- Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B: Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. *Am J Kidney Dis* 45: 415–421, 2005
- Nathanson S, Fremaux-Bacchi V, Deschenes G: Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. *Pediatr Nephrol* 16: 554–556, 2001
- Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH:



- Challenges in the management of infantile factor H associated hemolytic uremic syndrome. *Pediatr Nephrol* 19: 908–911, 2004
28. Davin JC, Olie KH, Verlaak R, Horuz F, Florquin S, Weening JJ, Groothoff JW, Strain L, Goodship TH: Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: Concordant presentation, discordant response to treatment. *Am J Kidney Dis* 47: e27–e30, 2006
  29. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship HT, Remuzzi G: Outcome of renal transplantation in patients with non-Shiga-toxin associated hemolytic syndrome: Prognostic significance of genetic background. *Clin J Am Soc Nephrol* 1: 88–99, 2006
  30. Kavanagh D, Goodship TH: Membrane cofactor protein and factor I: Mutations and transplantation. *Semin Thromb Haemost* 32: 155–159, 2006
  31. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat C, Deng HW, Goodship TH: The development of atypical HUS is influenced by susceptibility factors in factor H and membrane cofactor protein: Evidence from two independent cohorts. *J Med Genet* 42: 852–856, 2005
  32. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Hum Mol Genet* 12: 3385–3395, 2003
  33. Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, Choi Y: Attempted treatment of factor H deficiency by liver transplantation. *Pediatr Nephrol* 19: 454–458, 2004
  34. Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, Gridelli B: Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. *Lancet* 359: 1671–1672, 2002
  35. Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M: Hemolytic uremic syndrome: A fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation. *Am J Transplant* 5: 1146–1150, 2005
  36. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH: Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. *Am J Transplant* 6: 1948–1952, 2006